glp 1 crohn's disease Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation GLP-1 Agonists and Crohn's Disease:

CKD: Control diabetes & hypertension

When comparing BA concentrations between FM subjects and HC, deoxycholic acid (DCA) showed a nominal group difference, but this did not remain significant after correction for multiple testing ( P = 0.013) (Table 2

Lillys Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease

Therapeutically, it modulates immune responses and, when combined with Bifidobacterium bifidum , significantly reduces the incidence of rotavirus-induced gastroenteritis in pediatric populations